1-2 of 2
Xen Ianopulos, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Hun Ju Lee, MD, Michael Y. Choi, MD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Jacqueline C. Barrientos, MD, Nicole Lamanna, MD, Alec Goldenberg, MD, Iris Isufi, MD, Joseph Tuscano, MD, Suki Subbiah, MD, Jean L. Koff, MD, Lori A. Leslie, MD, Gina G Chung, MD, Elizabeth K Weihe, MD, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Frank J Hsu, MD, Michael Wang, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-141917
Published: 2020
Journal Articles

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Michael Y. Choi, MD, Emanuela M. Ghia, PhD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Hun Ju Lee, Jacqueline C. Barrientos, MD MS, Nicole Lamanna, MD, Alec Goldenberg, Dimitrios Tzachanis, MD PhD, Erin G. Reid, MD MS, Elizabeth K Weihe, MD, Laura Z. Rassenti, PhD, Iris Isufi, MD, Stewart Bieler, BA, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1755.
https://doi.org/10.1182/blood-2019-131498
Published: 2019